3Cascinu S,Labiance R,Alessandroni P,et al.Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil,cisplatin,epi-doxorubicin:bs-leucovorin,glutathione and filgrastim:a report from the Italian group for the study of Digestive Tract Cancer[J].Clin Oncol,1997,15(1):3313-3319.
5Bodley A,LiuLF,Israel M,et al.DNA topoisomerase Ⅱ-mediated interaction of doxorubicin and daunorubicin congeners with DNA[J].Cancer Res,1989,49(21):5959-5978.
6Harvey JH,Smith FP,Sehien PS.5-fluorouracil,Mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract[J].J clin Oncol,1984,2:1245.
二级参考文献20
1Wang Z，Mol Pharmacol，1996年，49卷，269页
2李继华，中国肿瘤临床，1996年，23卷，134页
3李建人，中华理疗杂志，1995年，18卷，1313页
4Tan K B，J Natl Cancer Inst，1989年，81卷，1732页
5Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892.
6Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271.
7Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2.
8Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7.
9Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13.
10Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606.
